Although Novo Nordisk still doesn't want to report the individual sales figures for its two obesity treatments – Saxenda and its heir, Wegovy – the positive progress in the business area is there for anyone to see in Wednesday's quarterly report.
In the first nine months of the year, Novo Nordisk total sales for the weight loss treatments amounted to DKK 5.9bn (USD 919m), beating full-year sales figures from the business of DKK 5.6bn (USD 872.2m) from 2020. That figure consisted only of Saxenda sales, as Wegovy was only introduced to the US market in June of this year – which is also its only market so far.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Production Director 
System Sales Development Consultant - Investment Projects, Merck Millipore 
2 Sales Representatives and Product Specialists 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Key Account Manager, Europe and Asia 
SAP System Specialist (Product Supply) – Business Application Services 
Director Global Engineering 
Analytical Coordinator for Analytical Development 
Biostatistician 
Clinical Trial Manager 
Clinical Trial Manager for development of in vitro diagnostics 
Senior Chemical Safety Advisor 
Director for innovative pre-clinical testing unit 
Senior Manager, Clinical Trial Budget 
Client Talent Acquisition Specialist 
Nordic Medical Affairs Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s